Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis. Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus.
Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.
Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Pittsburgh-based food and fuel retailer Giant Eagle, Inc. launched its free antibiotics program in September of 2009, and is pleased to announce that the program has resulted in more than $3 million in free prescriptions for customers in the company's four-state operating area.
Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.
Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.
A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist.
Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.
Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.
Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.
Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today the publication of a scientific paper in the journal Photochemistry and Photobiology that details in vitro and human data demonstrating the unique and patented mechanism-of-action for its Noveon® dual-wavelength device, as well as positive efficacy and safety data.
InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).
At a time when many families affected by a difficult economy are struggling with the costs of prescription medications, supermarket retailer Giant Eagle, Inc. is making ten broadly used generic prescription antibiotics in 46 common dosages available for free every day at all of its 210 in-store pharmacies.
Some disease-causing bacteria are becoming resistant to antibiotics because they have peculiar sex lives, say researchers publishing new results today in the journal Science.
Data published online and in an upcoming print issue of The Lancet show that Gleevec (imatinib mesylate) tablets, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.
Long-term use of a macrolide antibiotic may reduce the frequency of exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD) by as much as 35 percent, according to a London-based study.
New research has linked the practice of giving antibiotics to some women at risk of premature birth to cerebral palsy and other problems in infants.
Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).
Group B streptococcus, a major cause of serious infections, declined about 25 percent among infants younger than 7 days from 1999 to 2005, but increased nearly 50 percent among persons 15 to 64 years old, according to a study in the May 7 issue of JAMA, the Journal of the American Medical Association.
Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs.